$RGNX

Simply Wall St reports REGENXBIO (RGNX) fell about 5% to $10.72 after Q2 results. The company reported Q2 revenue of about $108.0 million versus $21.4 million a year earlier, net income of $22.7 million versus a $70.9 million loss, and basic EPS of about $0.43. The article cites an extended cash runway supported by AbbVie funding and an equity raise, while noting ongoing regulatory and safety risks.

RBC says Regenxbio is on track for Duchenne approval as new data strengthens the case, according to the bank. Separately, Barclays downgraded REGENXBIO to Equalweight from Overweight and set a $12 price target, according to the report. The stock was trading around $10.72 at market close.

REGENXBIO (Nasdaq: RGNX) reported Q2 2026 results and pipeline updates. It said its Phase III AFFINITY DUCHENNE trial met its primary endpoint (p<0.0001) and it dosed the first patient in the Phase IIb/III NAAVIGATE diabetic retinopathy study. The FDA reaffirmed the path for RGX-121 BLA resubmission in Q3 2026. Cash was $105.5m at June 30, 2026, with pro forma ~$313m after July funding.

REGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rgnx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights • RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 • Lon

REGENXBIO Inc. (Nasdaq: RGNX) said it will hold a conference call on Aug. 6 at 8:00 a.m. ET to discuss its second-quarter 2026 financial results for the period ended June 30, 2026, and operational highlights. A webcast replay will be posted on its investor website shortly after the call.

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

REGENXBIO (Nasdaq: RGNX) reported long-term follow-up data for investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD and diabetic retinopathy at ASRS. Wet AMD results showed stable or improved vision through 5 years and reduced anti-VEGF injections, with no new intraocular inflammation. DR data showed 55% >2-step DRSS improvement at 2.5 years. Pivotal topline data with AbbVie expected Q4 2026.

U.S. stocks fell mid-session, with the Nasdaq down 0.80% and the S&P 500 down 0.51%. Energy shares rose 1.4%. Travelers Companies (TRV) reported Q2 EPS of $10.04 versus $5.38 expected, and sales of $12.153B versus $11.346B expected. Oil rose 4% to $82.06.

Regenxbio Inc. (RGNX) shares fell about 13% after the company priced a $100 million public offering of common stock and pre-funded warrants. According to the company, it will sell about 10 million common shares at $9.00 and about 1.11 million pre-funded warrants at $8.9999 each. Closing is scheduled for July 20, 2026.

REGENXBIO Inc. (RGNX) priced a $100 million public offering of common stock and pre-funded warrants, sending shares down about 20%. The deal includes 10,003,889 shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999 each. Closing is set for July 20, 2026, with an underwriters’ option for up to 1,667,250 more shares.